TP53 and cancer: TRAIL binds to the p53 target gene DR5 (Wu et al., 1997) to induce apoptosis in a wide variety of cancer types while maintaining cancer cell specificity (Smyth et al., 2003), making it an attractive target for combination with immunotherapy.